PharmaEssentia stock

6446 · TWSE · TWD

Compare PharmaEssentia
$1,100.00Change from previous close: −8.71%Absolute change: −$105.00

Close · November 20, 2026

Price history

+156.62% over the period

1 year: from $428.66 (November 20, 2025) to $1,100.00 (November 20, 2026), +156.62%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$1,100.00
October 30, 2026$1,190.00
September 30, 2026$1,215.00
August 31, 2026$1,395.00
July 31, 2026$1,060.00
June 30, 2026$1,207.99
May 29, 2026$838.38
April 30, 2026$595.88
March 31, 2026$540.89
February 26, 2026$652.68
January 30, 2026$694.15
December 31, 2025$423.70
November 28, 2025$465.17
November 20, 2025$428.66

At a glance

  • The company

    Biopharmaceutical company developing specialty pharmaceutical products and treatments for blood disorders and cancers

  • Latest results

    Quarter to September 30, 2026 · EPS $7.08 (estimate $6.81)

TickerLandia's take on PharmaEssentia

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$407.92
52-wk high$1,645.00

−33.13% from the 52-week high

Analysts · 8 analysts

Average target$1,437.27+30.66% vs. price

Buy 7 · Hold 1 · Sell 0 · Buy

TickerLandia Fingerprint: PharmaEssentia

Compared with similar companies: very high growth, very low earnings stability, and very high profitability.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

PharmaEssentia is pricier than similar companies

PharmaEssentia's P/E (trailing 12 months): 74.1, +158% against the median of a group of 11 similar companies (28.7).

Compared with 11 similar companies

PharmaEssentia's metrics compared with similar companies
MetricPharmaEssentiaPosition in the groupBand
P/E (trailing 12 months)74.1High
Forward P/E29.3High
Operating margin38.4%High
ROE23.3%High
Debt/equity0.03Middle

Grey band: the middle half of the group; tick: the median; dot: PharmaEssentia. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$6.86B

Latest quarter · Q2 2026

Net income

$2.53B

Latest quarter · Q2 2026

Quarterly net margin

36.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$526.33B
P/E
74.1
EPS
$21.98
Volume
5.63M
Daily trading
€119.22M
Dividend yield
0.14%
Last ex-dividend on July 9, 2026

How PharmaEssentia is changing

All results
  • Revenue grew 94.8% a year on average over the last 5 years

  • Operating margin rose from −70.4% to 31.5%

  • Less cash than profit: free cash flow equal to 41% of net income

Returns

PharmaEssentia returns with dividends

$1,000 invested in PharmaEssentia 5 years ago, on November 22, 2021, would be worth $7,576 today: +657.58% in total, +50.00% per year. This is the price return only: dividends are excluded.

PeriodPharmaEssentia$1,000 becomes
1 month−4.76%$952
6 months+54.65%$1,547
Year to date+159.62%$2,596
1 year+156.91%$2,569
3 years+275.10%$3,751
5 years+657.58%$7,576
10 years+634.96%$7,350

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

PharmaEssentia: technical analysis

PharmaEssentia shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 30.6% below its all-time closing high ($1,585.00, August 26, 2026).

Trend
No clear trend
RSI (14 sessions)
38
Between 30 and 70
vs 200-session average
+12.88%

Active signals

  • The last session opened more than 3% below the previous close.

Support and resistance

Price areas where PharmaEssentia has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$1,290.00+17.27%2 touches, last on October 16, 2026
  2. Resistance$1,240.00+12.73%2 touches, last on October 1, 2026
  3. Resistance$1,147.50+4.32%6 touches, last on October 27, 2026
  4. Last price$1,100.00
  5. Support$900.59−18.13%2 touches, last on June 10, 2026
  6. Support$696.85−36.65%2 touches, last on February 26, 2026
  7. Support$605.44−44.96%5 touches, last on April 20, 2026

Volatility and risk

Volatility (60 sessions, annualised)
59.4%
Largest fall in the last year
−30.60%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

PharmaEssentia: seasonality

Average monthly price change over 13 years

+3.0%Jan+3.7%Feb−8.7%Mar−2.1%Apr+8.7%May+12.0%Jun−0.8%Jul+1.3%Aug−1.2%Sep−4.7%Oct+20.7%Nov+2.4%Dec

Over the last 13 years, the strongest month for PharmaEssentia has been November: +20.67% on average, positive in 9 years out of 12. The weakest has been March: −8.69% on average, positive in 3 years out of 12.

Show chart data
MonthAverageMedianPositive years
January+3.04%−2.23%5 of 12
February+3.74%+2.92%7 of 12
March−8.69%−6.00%3 of 12
April−2.13%−4.85%4 of 13
May+8.66%−1.66%6 of 13
June+12.02%+9.60%9 of 13
July−0.77%+0.70%7 of 13
August+1.32%+0.10%7 of 13
September−1.15%−4.39%5 of 13
October−4.74%−3.30%4 of 13
November+20.67%+9.38%9 of 12
December+2.44%−2.36%5 of 12

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

PharmaEssentia and its competitors

With revenue of TWD 15.6 billion in the fiscal year ended December 2025, PharmaEssentia Corporation develops specialty pharmaceutical reagents, active pharmaceutical ingredients and new drugs, with activities in the Americas, Europe, Asia and Taiwan. Its main product, BESREMi, is used to treat polycythemia vera and essential thrombocythemia, and the company also works on treatments for adult T-cell leukemia. Its pipeline spans cancer and immunology programs, including PEG-IL-2, PD-1-IL-2v and TCR-T therapies for solid tumors.

Headquarters
Taipei, Taiwan
Employees
131
Founded
1990
Chief executive
Ko-Chung Lin
PharmaEssentia and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
PharmaEssentia6446$15.94B38.4%74.1+54.65%
Shionogi4507$16.75B31.6%11.2+2.83%
Yunnan Baiyao Group000538$15.07B11.2%19.4+11.07%
Laurus LabsLAURUSLABS$14.13B24.1%97.8+68.58%
Torrent PharmaceuticalsTORNTPHARM$19.25B22.2%79.2+5.88%
Zydus LifesciencesZYDUSLIFE$12.92B17.2%28.7+15.29%

Same industry or related industries, similar size. Compare PharmaEssentia with its competitors · Full profile